{"id":"mfolfox6-or-capox","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The regimen works by inhibiting DNA synthesis and function in cancer cells, leading to cell death. Oxaliplatin interferes with DNA replication, while 5-fluorouracil and leucovorin inhibit thymidylate synthase, a key enzyme in DNA synthesis.","oneSentence":"mFOLFOX6 or CAPOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:12.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colon cancer"}]},"trialDetails":[{"nctId":"NCT06258525","phase":"PHASE2","title":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-03","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":30},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT04430738","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-09-15","conditions":"Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma","enrollment":40},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT05111626","phase":"PHASE3","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":515},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT06052332","phase":"NA","title":"Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2024-02-07","conditions":"Locally Advanced Rectal Cancer, Older People","enrollment":230},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT04662710","phase":"PHASE3","title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-30","conditions":"Advanced/Metastatic Gastroesophageal Adenocarcinoma","enrollment":895},{"nctId":"NCT05482893","phase":"PHASE1, PHASE2","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2023-03-15","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)","enrollment":258},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT06048081","phase":"","title":"Early Access Program for Zolbetuximab","status":"AVAILABLE","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer, Metastatic Gastric Adenocarcinoma Cancer","enrollment":""},{"nctId":"NCT06834126","phase":"PHASE1","title":"Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-04-07","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":36},{"nctId":"NCT05870800","phase":"PHASE2","title":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2025-06-15","conditions":"Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer","enrollment":28},{"nctId":"NCT06794086","phase":"PHASE3","title":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-04-10","conditions":"Colorectal Cancer, Liver Metastases","enrollment":24},{"nctId":"NCT02572141","phase":"PHASE3","title":"FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2015-01-01","conditions":"Colon Cancer","enrollment":738},{"nctId":"NCT05268510","phase":"PHASE2","title":"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2022-09-15","conditions":"Esophagogastric Adenocarcinoma","enrollment":31},{"nctId":"NCT06767007","phase":"PHASE2","title":"SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-06","conditions":"Unresectable Locally Recurrent Rectal Cancer","enrollment":31},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT04246684","phase":"PHASE3","title":"Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Dr. med. Claus Rödel","startDate":"2020-11-05","conditions":"Rectal Cancer Stage III","enrollment":702},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT05202314","phase":"NA","title":"Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer","status":"RECRUITING","sponsor":"Beijing Chao Yang Hospital","startDate":"2021-12-12","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":20},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT04418895","phase":"PHASE2","title":"Neoadjuvant Therapy for Localized Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-08-13","conditions":"Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT02435927","phase":"PHASE1","title":"ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2014-08","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT04288999","phase":"PHASE3","title":"Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2019-10-01","conditions":"Rectal Cancer Recurrent","enrollment":110},{"nctId":"NCT04039360","phase":"","title":"SEMS Placement Followed by Chemotherapy and Surgery for Obstructing Left-sided Colonic Cancer","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2014-05-01","conditions":"Complication of Treatment","enrollment":11},{"nctId":"NCT01092481","phase":"PHASE3","title":"Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-01-26","conditions":"Colon Cancer","enrollment":1580},{"nctId":"NCT03415763","phase":"PHASE3","title":"Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy","status":"UNKNOWN","sponsor":"LI XIN-XIANG","startDate":"2018-11-05","conditions":"Rectal Neoplasms","enrollment":764},{"nctId":"NCT00070122","phase":"PHASE3","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-04","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":2200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["5-Fu-leucovorin-oxaliplatin or xeloda-oxaliplatin"],"phase":"phase_3","status":"active","brandName":"mFOLFOX6 or CAPOX","genericName":"mFOLFOX6 or CAPOX","companyName":"LI XIN-XIANG","companyId":"li-xin-xiang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFOX6 or CAPOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to target rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}